Thus, targeting tumor-resident NK cell activity has the potential to overcome certain resistance mechanisms to ICIs mediated by poor neoantigen presentation and has the potential to increase ICI response rates by potentiating CD8+ T-cell priming. This evidence concerns the gene CD8A and neoplasm.